# Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

> **NCT02371746** · PHASE2 · COMPLETED · sponsor: **Envisia Therapeutics** · enrollment: 41 (actual)

## Conditions studied

- Glaucoma and Ocular Hypertension

## Interventions

- **DRUG:** ENV515-3 Travoprost XR
- **DRUG:** ENV515-1 Travoprost XR
- **DRUG:** ENV515-3-2 Travoprost XR

## Key facts

- **NCT ID:** NCT02371746
- **Lead sponsor:** Envisia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-02-13
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02371746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02371746, "Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02371746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*